Related Experiment Video
Updated: Jul 7, 2026

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography
Published on: August 11, 2023
Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration
Teresa Diago1, Jose S Pulido, Julian R Molina
1Department of Ophthalmology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Abstract:
Angiogenesis is a common factor in the pathogenesis of cancer and in exudative age-related macular degeneration (AMD). Therefore, angiogenesis inhibition has been developed as a therapeutic strategy. We report 2 cases of recurrent exudative AMD in which oral sorafenib, a tyrosine kinase inhibitor approved for cancer, was added to intravitreal ranibizumab, an antibody to vascular endothelial growth factor. These 2 patients were followed up by determination of visual acuity, fluorescein angiography, fundoscopy, and optical coherence tomography. The visual acuity of 1 patient improved from 20/70 to 20/60 while he was receiving sorafenib therapy; that of the other did not. Marked improvement was noted in both patients on optical coherence tomography. Additionally, both patients appeared to receive some benefit when low-dose oral sorafenib was used as monotherapy after its initial addition to ranibizumab therapy. Randomized trials of adding sorafenib to standard therapy for patients with neovascular AMD should be considered.
Insights
Adding sorafenib to ranibizumab therapy showed potential benefits for patients with wet age-related macular degeneration (AMD). Optical coherence tomography revealed marked improvement in both cases, suggesting further investigation in randomized trials.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Angiogenesis is implicated in both cancer and exudative age-related macular degeneration (AMD).
- Angiogenesis inhibition is a therapeutic strategy for these conditions.
- Standard treatment for neovascular AMD often involves anti-vascular endothelial growth factor (VEGF) agents.
Observation:
- Two cases of recurrent exudative AMD were treated with oral sorafenib (a tyrosine kinase inhibitor) added to intravitreal ranibizumab (an anti-VEGF antibody).
- Patients were monitored using visual acuity, fluorescein angiography, fundoscopy, and optical coherence tomography (OCT).
Findings:
- One patient experienced improved visual acuity from 20/70 to 20/60 with sorafenib therapy.
- Both patients showed marked improvement on OCT.
- Both patients appeared to benefit from low-dose oral sorafenib monotherapy after initial combination treatment.
Implications:
- Adding sorafenib to standard therapy may benefit patients with neovascular AMD.
- Further investigation through randomized clinical trials is warranted.
- Sorafenib's potential role in managing exudative AMD warrants exploration.
Related Concept Videos
Diabetic Retinopathy
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview